Naomi Komatsuzaki - Academia.edu (original) (raw)

Naomi Komatsuzaki

Related Authors

João Carmo

Fred Opperdoes

Santosh Gahukar

Dr. Panjabrao Deshmukh Krishi Vidyapith, Akola, Maharashtra, India

Dirk K F Meijer

Uploads

Papers by Naomi Komatsuzaki

Research paper thumbnail of Abstract 5570: Development of piggyBac transposon-mediated HER2-CAR-T cells for the treatment of solid tumors

Cancer Research

Background: Although chimeric antigen receptor (CAR)-T therapies have achieved remarkable success... more Background: Although chimeric antigen receptor (CAR)-T therapies have achieved remarkable success in the treatment of hematologic malignancies, the outcome for patients with solid tumors remains poor. There are several reasons behind this, including exhaustion of CAR-T cell, poor homing and penetration in the tumor, and the lack of persistence in the immunosuppressive tumor microenvironment. To solve these problems, we have developed HER2-CAR-T cells (BP2301) using the piggyBac (PB) transposon-based gene transfer system. Methods and Results: Second generation HER2-CAR construct plus PB transposase were introduced into autologous peripheral blood mononuclear cells (PBMC) by electroporation. These cells were activated with UV-inactivated genetically-engineered antigen presenting autologous PBMC (AP cells) expressing HER2, CD80, and 4-1BBL, and propagated for 14 days to obtain the final product (BP2301). BP2301 exhibited dominant fraction of less exhausted stem cell memory-like T cells...

Research paper thumbnail of Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe

The Lancet Infectious Diseases, 2010

Research paper thumbnail of Abstract 5570: Development of piggyBac transposon-mediated HER2-CAR-T cells for the treatment of solid tumors

Cancer Research

Background: Although chimeric antigen receptor (CAR)-T therapies have achieved remarkable success... more Background: Although chimeric antigen receptor (CAR)-T therapies have achieved remarkable success in the treatment of hematologic malignancies, the outcome for patients with solid tumors remains poor. There are several reasons behind this, including exhaustion of CAR-T cell, poor homing and penetration in the tumor, and the lack of persistence in the immunosuppressive tumor microenvironment. To solve these problems, we have developed HER2-CAR-T cells (BP2301) using the piggyBac (PB) transposon-based gene transfer system. Methods and Results: Second generation HER2-CAR construct plus PB transposase were introduced into autologous peripheral blood mononuclear cells (PBMC) by electroporation. These cells were activated with UV-inactivated genetically-engineered antigen presenting autologous PBMC (AP cells) expressing HER2, CD80, and 4-1BBL, and propagated for 14 days to obtain the final product (BP2301). BP2301 exhibited dominant fraction of less exhausted stem cell memory-like T cells...

Research paper thumbnail of Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe

The Lancet Infectious Diseases, 2010

Log In